OmniaBio is a CDMO specializing in cell and gene therapy, offering advanced cell-based processes and gene delivery services. Covering the full product lifecycle, from preclinical to commercial manufacturing, mniaBio focuses on immune cell therapies, pluripotent stem cells, and lentiviral vectors. The company is dedicated to advancing programs, enhancing affordability, and ensuring patient access to transformative treatments.